The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
Open accessAbstract
The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that interrupt proliferation of malignant cells by inhibiting progression through the cell cycle. Three such inhibitors, palbociclib, ribociclib, and abemaciclib were recently approved for breast cancer treatment in various settings and combination regimens. On the basis of their impressive efficacy, all three CDK4/6 inhibitors now play an important role in the treatment of patients with HR+, HER2- breast cancer; however, their optimal use still needs to be established. The three drugs have many similarities in both pharmacokinetics and pharmacodynamics. However, there are some differences on the basis of which the choice for a particular CDK4/6 inhibitor for an individual patient can be important. In this article, the clinical pharmacokinetic and pharmacodynamic profiles of the three CDK4/6 inhibitors are reviewed and important future directions of the clinical applicability of CDK4/6 inhibitors will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,508
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“HR hazard ratio, mo months, NR not reported, IDFS invasive disease free survival Palbociclib (Ibrance®) PD-0332991 [8, 11, 50, 55, 63, 119] Ribociclib (Kisqali®) LEE011 [9, 13, 50, 119, 120] Abemaciclib (Verzenios®) LY2835219 [10, 50, 58, 62, 119]”
BackgroundShou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., Zhang, Q. Y., Martinez Rodriguez, J. L., Campone, M., Hamilton, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02514 · Cited by 1,022
Overall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4782 · Cited by 991
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911149 · Cited by 865
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
The retinoblastoma tumour suppressor in development and cancer
Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-018-0097-z · Cited by 685
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
O'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., Garcia-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650
Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061960 · Cited by 618
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 501
Targeting CDK4/6 in patients with cancer
Hamilton, E., & Infante, J. R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.002 · Cited by 481
Duncan, K., Abudu, R., Cira, M. K., & Pyle, D. H. M. (2019) · Journal of Global Oncology · doi:10.1200/jgo.19.11000 · Cited by 480
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470
Spring, L. M., Wander, S. A., Andre, F., Moy, B., Turner, N. C., & Bardia, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30165-3 · Cited by 468
Turner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., DeMichele, A., Harbeck, N., André, F., Bayar, M. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00925 · Cited by 449
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0300 · Cited by 444
Wander, S. A., Cohen, O., Gong, X., Johnson, G. N., Buendia-Buendia, J. E., Lloyd, M. R., Kim, D., Luo, F., Mao, P., Helvie, K., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1390 · Cited by 429
O’Leary, B., Hrebien, S., Morden, J. P., Beaney, M., Fribbens, C., Huang, X., Liu, Y., Bartlett, C. H., Koehler, M., Cristofanilli, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03215-x · Cited by 414
Condorelli, R., Spring, L., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 394
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366
Ma, C. X., Gao, F., Luo, J., Northfelt, D. W., Goetz, M., Forero, A., Hoog, J., Naughton, M., Ademuyiwa, F., Suresh, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3206 · Cited by 366
CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells
Laurenti, E., Frelin, C., Xie, S., Ferrari, R., Dunant, C. F., Zandi, S., Neumann, A., Plumb, I., Doulatov, S., Chen, J., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.01.017 · Cited by 342
Parise, C. A., Bauer, K. R., Brown, M. M., & Caggiano, V. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00822.x · Cited by 331
Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 317
CDK4/6 inhibition in breast cancer: current practice and future directions
Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786451 · Cited by 316
Gao, J. J., Cheng, J., Bloomquist, E., Sanchez, J., Wedam, S. B., Singh, H., Amiri-Kordestani, L., Ibrahim, A., Sridhara, R., Goldberg, K. B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30804-6 · Cited by 289
Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Verheijen, R. B., Yu, H., Schellens, J. H. M., Beijnen, J. H., Steeghs, N., & Huitema, A. D. R. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.787 · Cited by 278
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I., Sampath, D., Giltnane, J., Lacap, J. A., Crocker, L., Young, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0369 · Cited by 268
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Tolaney, S. M., Wardley, A. M., Zambelli, S., Hilton, J. F., Troso-Sandoval, T. A., Ricci, F., Im, S.-A., Kim, S.-B., Johnston, S. R., Chan, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30112-1 · Cited by 258
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., Colleoni, M., Iwata, H., Harbeck, N., Cristofanilli, M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0097 · Cited by 249
Lobbezoo, D. J. A., van Kampen, R. J. W., Voogd, A. C., Dercksen, M. W., van den Berkmortel, F., Smilde, T. J., van de Wouw, A. J., Peters, F. P. J., van Riel, J. M. G. H., Peters, N. A. J. B., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2711-y · Cited by 248
Kozyra, M., Ingelman-Sundberg, M., & Lauschke, V. M. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.33 · Cited by 230
Hurvitz, S. A., Martin, M., Press, M. F., Chan, D., Fernandez-Abad, M., Petru, E., Rostorfer, R., Guarneri, V., Huang, C.-S., Barriga, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1425 · Cited by 227
Targeting the RB-E2F pathway in breast cancer
Johnson, J., Thijssen, B., McDermott, U., Garnett, M., Wessels, L. F. A., & Bernards, R. (2016) · Oncogene · doi:10.1038/onc.2016.32 · Cited by 199
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., McNulty, A. M., Gong, X., Boehnke, K., Du, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17778 · Cited by 196
Giuliano, M., Schettini, F., Rognoni, C., Milani, M., Jerusalem, G., Bachelot, T., De Laurentiis, M., Thomas, G., De Placido, P., Arpino, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30420-6 · Cited by 186
Rugo, H. S., Huober, J., García-Sáenz, J. A., Masuda, N., Sohn, J. H., Andre, V. A. M., Barriga, S., Cox, J., & Goetz, M. (2021) · The Oncologist · doi:10.1002/onco.13531 · Cited by 183
Spring, L. M., Zangardi, M. L., Moy, B., & Bardia, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0142 · Cited by 178
Michaloglou, C., Crafter, C., Siersbaek, R., Delpuech, O., Curwen, J. O., Carnevalli, L. S., Staniszewska, A. D., Polanska, U. M., Cheraghchi-Bashi, A., Lawson, M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0537 · Cited by 177
Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw139 · Cited by 176
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barbero, B., Álvarez-Fernández, M., Zapatero-Solana, E., El Bakkali, A., Menéndez, M. D. C., López-Casas, P. P., Di Domenico, T., Xie, T., VanArsdale, T., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 176
Weiss, J. M., Csoszi, T., Maglakelidze, M., Hoyer, R. J., Beck, J. T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C. M., Boccia, R. V., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz278 · Cited by 165
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
McClendon, A. K., Dean, J. L., Rivadeneira, D. B., Yu, J. E., Reed, C. A., Gao, E., Farber, J. L., Force, T., Koch, W. J., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21127 · Cited by 163
Lange, C. A., & Yee, D. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0112 · Cited by 148
O’Leary, B., Cutts, R. J., Huang, X., Hrebien, S., Liu, Y., André, F., Loibl, S., Loi, S., García-Murillas, I., Cristofanilli, M., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa087 · Cited by 131
Tate, S. C., Cai, S., Ajamie, R. T., Burke, T., Beckmann, R. P., Chan, E. M., De Dios, A., Wishart, G. N., Gelbert, L. M., & Cronier, D. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2846 · Cited by 130
Tan, A. R., Wright, G. S., Thummala, A. R., Danso, M. A., POPOVIC, L. S., Pluard, T., Han, H. S., Vojnović, Ž., Vasev, N., Ma, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30616-3 · Cited by 125
O’Brien, N. A., Conklin, D. F., Beckmann, R. P., Luo, T., Chau, K., Thomas, J. D., Nulty, A. M., Marchal, C. C., Kalous, O., von Euw, E., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0290 · Cited by 116
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib
Chong, Q.-Y., Kok, Z. H., Bui, N.-L.-C., Xiang, X., Wong, A. L., Yong, W. P., Sethi, G., Lobie, P. E., Wang, L., & Goh, B.-C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104686 · Cited by 115
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions
Milani, A., Geuna, E., Mittica, G., & Valabrega, G. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.990 · Cited by 114
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
Kloth, J. S. L., Pagani, A., Verboom, M. C., Malovini, A. L., Napolitano, C., Kruit, W. H. J., Sleijfer, S., Steeghs, N., Zambelli, A., & Mathijssen, R. H. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.82 · Cited by 107
Self-citationVerma, S., O’Shaughnessy, J., Burris, H. A., Campone, M., Alba, E., Chandiwana, D., Dalal, A. A., Sutradhar, S., Monaco, M., & Janni, W. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4769-z · Cited by 100
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Scott, S. C., Lee, S. S., & Abraham, J. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.01.006 · Cited by 96
Im, S., Mukai, H., Park, I. H., Masuda, N., Shimizu, C., Kim, S.-B., Im, Y., Ohtani, S., Bartlett, C. H., Lu, D. R., et al. (2019) · Journal of Global Oncology · doi:10.1200/jgo.18.00173 · Cited by 95
Dieras, V. C., Harbeck, N., Joy, A. A., Gelmon, K. A., Ettl, J., Verma, S., Lu, D. R., Gauthier, E. R., Schnell, P., Mori, A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0019 · Cited by 93
Samant, T. S., Dhuria, S. V., Lu, Y., Laisney, M., Yang, S., Grandeury, A., Mueller‐Zsigmondy, M., Umehara, K., Huth, F., Miller, M. C., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.940 · Cited by 90
Kaufman, P. A., Toi, M., Neven, P., Sohn, J., Grischke, E., Andre, V., Stoffregen, C., Shekarriz, S., Price, G. L., Carter, G. C., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0551 · Cited by 89
de Gooijer, M. C., Zhang, P., Thota, N., Mayayo‐Peralta, I., Buil, L. C. M., Beijnen, J. H., & van Tellingen, O. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0266-y · Cited by 88
Duan, J., Tao, J., Zhai, M., Li, C., Zhou, N., Lv, J., Wang, L., Lin, L., & Bai, R. (2018) · Oncotarget · doi:10.18632/oncotarget.25008 · Cited by 87
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer
Aggelis, V., & Johnston, S. R. D. (2019) · Drugs · doi:10.1007/s40265-019-01208-8 · Cited by 78
Tate, S. C., Sykes, A. K., Kulanthaivel, P., Chan, E. M., Turner, P. K., & Cronier, D. M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0559-8 · Cited by 77
van Ommen‐Nijhof, A., Konings, I. R. H. M., van Zeijl, C. J. J., Groot, C. A. U., van der Noort, V., Jager, A., & Sonke, G. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-4978-1 · Cited by 70
Self-citationLadumor, M. K., Bhatt, D. K., Gaedigk, A., Sharma, S., Thakur, A., Pearce, R. E., Leeder, J. S., Bolger, M. B., Singh, S., & Prasad, B. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086462 · Cited by 70
Physiologically Based Pharmacokinetic Modeling of Palbociclib
Yu, Y., Loi, C., Hoffman, J., & Wang, D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.792 · Cited by 68
Fujiwara, Y., Tamura, K., Kondo, S., Tanabe, Y., Iwasa, S., Shimomura, A., Kitano, S., Ogasawara, K., Turner, P. K., Mori, J., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3085-8 · Cited by 66
Bisi, J., Sorrentino, J. A., Jordan, J. L., Darr, D. D., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2017) · Oncotarget · doi:10.18632/oncotarget.16216 · Cited by 65
Posada, M. M., Morse, B. L., Turner, P. K., Kulanthaivel, P., Hall, S. D., & Dickinson, G. L. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1584 · Cited by 58
Sun, W., O'Dwyer, P. J., Finn, R. S., Ruiz-García, A., Shapiro, G. I., Schwartz, G. K., DeMichele, A. M., & Wang, D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.902 · Cited by 50
P‑glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability
Martínez-Chávez, A., van Hoppe, S., Rosing, H., Lebre, M. C., Tibben, M. M., Beijnen, J. H., & Schinkel, A. H. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00475 · Cited by 50
Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology
Groenland, S. L., van Nuland, M., Verheijen, R. B., Schellens, J. H. M., Beijnen, J. H., Huitema, A. D. R., & Steeghs, N. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0683-0 · Cited by 49
Durairaj, C., Ruiz-García, A., Gauthier, E. R., Huang, X., Lu, D. R., Hoffman, J., Finn, R. S., Joy, A. A., Ettl, J., Rugo, H. S., et al. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000589 · Cited by 48
The Breast Cancer Therapy Expert Group (BCTEG), Abraham, J., Coleman, R. E., ELIAS, A. D., Holmes, F. A., Kalinsky, K. M., Kittaneh, M., Lower, E. E., Mahtani, R. L., Mamounas, E., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4783-1 · Cited by 45
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment
Parylo, S., Vennepureddy, A., Dhar, V., Patibandla, P., & Sokoloff, A. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218770904 · Cited by 42
Shohdy, K. S., Lasheen, S., Kassem, L. M. H., & Abdel-Rahman, O. M. (2017) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617722516 · Cited by 39
Dhakal, A., Matthews, C. M., Levine, E. G., Salerno, K. E., Zhang, F., Takabe, K., Early, A., Edge, S. B., O'Connor, T., Khoury, T., et al. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.04.015 · Cited by 38
Effect of food on the bioavailability of palbociclib
Ruiz-García, A., Plotka, A., O’Gorman, M. T., & Wang, D. D. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3246-4 · Cited by 37
CDK4-6 inhibitors in breast cancer: current status and future development
Choo, J. R.-E., & Lee, S. C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541347 · Cited by 31
van Dyk, M., Marshall, J.-C. A., Sorich, M. J., Wood, L. S., & Rowland, A. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2450-4 · Cited by 30
Mayer, E. L., Gnant, M. I., DeMichele, A. M., Martín, M., Burstein, H. J., Prat, A., Rubovszky, G., Miller, K. D., Pfeiler, G., Winer, E. P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2240 · Cited by 29
Jin, D., Tran, N., Thomas, N. J., & Tran, D. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223555 · Cited by 27
Hussaarts, K. G. A. M., Berger, F. A., Binkhorst, L., Hoop, E. O., van Leeuwen, R. W. F., Alphen, R. J. V., Stein, D. M., de Groot, N. M. S., Mathijssen, R. H. J., & van Gelder, T. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2746-9 · Cited by 23
Self-citationAbstract 3101: In-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines
Lallena, M. J., Boehnke, K., Torres, R., Hermoso, A., Amat, J., Calsina, B., de Dios, A., Buchanan, S. G., Du, J., Beckmann, R. P., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-3101 · Cited by 22
Thakkar, D., & Kate, A. S. (2019) · Drug Testing and Analysis · doi:10.1002/dta.2725 · Cited by 20
Silberholz, J., Bertsimas, D., & Vahdat, L. T. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05208-w · Cited by 19
Mohammedi, L., Doula, F. D., Mesli, F., & SENHADJI, R. (2019) · African Health Sciences · doi:10.4314/ahs.v19i2.38 · Cited by 18
Li, H., & Zheng, B. (2019) · Medical Science Monitor · doi:10.12659/msm.914742 · Cited by 12
Azim, H. A., Dawood, S. S., El-Saghir, N. S., Kassem, L. M. H., & Azim, H. A. (2019) · The Breast Journal · doi:10.1111/tbj.13637 · Cited by 5
Cited by
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
Xia, T., Dai, X., Sang, M., Zhang, X., Xu, F., Wu, J., Shi, L., Wei, J., & Ding, Q. (2024) · Advanced Science · doi:10.1002/advs.202305142 · Cited by 52
Metadata
- Authors
- Braal, C. L., Jongbloed, E. M., Wilting, S. M., Mathijssen, R. H. J., Koolen, S. L. W., & Jager, A.
- Venue
- Drugs
- Published
- 2020-12-28
- Volume
- 81
- Issue
- 3
- Pages
- 317-331
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3116228263
- Cited by
- 438
- References
- 113
- FWCI
- 20.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.